Bioxyne directors awarded shares for meeting performance targets

Bioxyne Limited has issued a total of 18,000,000 ordinary fully paid shares to two key management personnel, Jason Hine and Samuel Watson, following the vesting of performance rights. These shares, issued on October 27, 2025, are a remuneration incentive tied to the achievement of performance milestones for the 2023 to 2025 period.

Mr. Hine, a director, acquired 4,500,000 ordinary shares, held indirectly through Hine Lamont Pty Ltd as trustee for the "Hine Lamont Family Trust." This transaction adjusted his indirect holding to 4,500,000 ordinary shares and 10,000,000 performance rights, in addition to his directly held 1,324,890 ordinary shares. Mr. Watson, also a director, received 13,500,000 ordinary shares, held through Breathe International Limited, in which he holds a controlling interest, and Zonetech Wellness Limited, a subsidiary.

Following this issuance, Mr. Watson's holdings now include 576,268,527 shares held by Breathe International Limited, 57,732,857 shares by Zonetech Wellness Limited, 14,499,362 shares held directly, and 20,000,000 performance rights. The new shares rank equally with existing issued securities and were valued at an estimated AUD0.043000 per security. The total number of quoted ordinary fully paid shares for Bioxyne Limited stands at 2,189,828,732.